Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Ahmed M Abou-Elseoud; Asmaa Mahmoud Mohamed Gaballah

doi:10.53730/ijhs.v5nS2.14971

Authors

Ahmed M. Abou-Elseoud General and Laparoscopic Surgery Registrar (Ali bn Ali Hospital Riyadh, Kingdom of Saudia Arabia)
Asmaa Mahmoud Mohamed Gaballah Ophthalmology Registrar, Ophthalmology Hospital Tanta Al Gharbia, Egypt

Keywords:

Gastric adenocarcinoma, Chemoradiotherapy, Gastro-esophageal junction, Relapse-free Survival

Abstract

Background: Adenocarcinomas of the gastro-esophageal junction (GEJ) are often lumped in therapeutic trials and analyzed with either esophageal cancer or gastric cancer. Aim: We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction. Patients and methods: This study was conducted at Ali bn Ali hospital in corporation with Soliman Fakeeh Hospital. This study was conducted on 505 patients with resected adenocarcinoma of the stomach or GEJ were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone, those were divided into two groups: Surgery only group (N=247), and Chemoradiotherapy group (N=258). Results: There was highly statistically significant difference between the studied groups regarding overall survival among all eligible patients with majority of dead rate in surgery only group (70.4%). And Relapse-free Survival among All Eligible Patients with majority of dead rate in Surgery only group (74.9%). While, there was no statistically significant difference regarding age sex, T stage, No. of positive nodes and location of primary tumor.

Downloads

Download data is not yet available.

References

Patrão AS, Papaxoinis G, Kordatou Z, Weaver JM, Owen-Holt V, Alkhaffaf B, Galloway S, Mansoor W. Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma. European Journal of Surgical Oncology. 2019 Mar 1;45(3):439-45.

Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close!. World journal of gastroenterology. 2015 Nov 11;21(41):11609.

Mamdani HK, Jalal SI. Advances and Controvarsies in the Management of Locally Advanced Gastro-esophageal Adenocarcioma. J Clin Gastroenterol Treat. 2016;2(010).

Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Management and Research. 2018 Jun 21:1605-18.

Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017 May 1;123(9):1497-506.

Simha V, Patil V, Joshi A, Prabhash K, Noronha V. Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers. Cancer Research, Statistics, and Treatment. 2019 Jul 1;2(2):172-81.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006 Jul 6;355(1):11-20.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine. 2001 Sep 6;345(10):725-30.

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). Journal of Clinical Oncology. 2017 Nov 11;35(32):3671.

MASASHI F, Mitsugu K, Tadatoshi T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surgery today: the Japanese journal of surgery. 2010 Apr 1;40(4):295-300.

Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surgery today. 2010 Apr; 40:295-300.

Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):4003-.

Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of clinical oncology. 2011 May 1;29(13):1715-21.

Kofoed SC, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scandinavian Journal of Surgery. 2012 Mar;101(1):26-31.

Gaast AV, Van Hagen P, Hulshof MC, Richel D, van Berge Henegouwen MI, Nieuwenhuijzen GA, et al, CROSS Study Group. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):4004-.

Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. European journal of cancer. 2013 Oct 1;49(15):3149-58.